mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy - 20/04/12
Corresponding author.Résumé |
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase. It is ubiquitously expressed in cells and is a therapeutic target for the cancer treatment arsenal. Despite the great responses obtained in tumors addicted to specific mutations or overactivation of key members of the mTOR pathway (HiF1⍺ in RCC, cyclin D1 in MCL, or TSC in SEGA), mTOR inhibitors as single agents have modest activity. Dual PI3K/mTOR kinase inhibitors have been developed with the idea of overcoming resistance to the mTOR inhibition through preventing the activation of PI3K/Akt as a result of release negative feedback loops.
Le texte complet de cet article est disponible en PDF.Keywords : mTOR, Inhibitor, Rapalog, Cancer
Plan
| Anna C. Ferrari participates in advisory boards for Novartis; Dendreon Corporation; Janssen Pharmaceuticals, Inc.; OSI Pharmaceuticals, Inc.; Astellas Pharma US, Inc.; OrhtoBiotech; Bayer Corporation; Merck & Co., Inc.; Osuka; Natrogene; Amgen, Inc.; Oxford BioMedica; and Cougar Biotechnology/Johnson & Johnson, and is a recipient of a grant from Novartis. |
Vol 26 - N° 3
P. 483-505 - juin 2012 Retour au numéro
Article précédent
- Therapeutic Antibodies Against Cancer
- Mark J. Adler, Dimiter S. Dimitrov
- Topoisomerase 1 Inhibitors and Cancer Therapy
- Julia Moukharskaya, Claire Verschraegen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?